No abstract

T cell receptor (TCR) γδ-expressing T lymphocytes compose evolutionarily conserved cells with paradoxical features. On the one hand, clonally expanded γδ T cells with unique specificities typify adaptive immunity. Conversely, large TCRγδ+ intraepithelial lymphocyte (γδ IEL) compartments exhibit limited TCR diversity and effect rapid, innate-like tissue surveillance. The development of several γδ IEL compartments depends upon epithelial Btnl/BTNL (butyrophilin-like) genes, which are members of the B7-superfamily of T cell co-stimulators. Here we show that Btnl/BTNL responsiveness is mediated by germline-encoded motifs within the cognate TCRVγ chains of mouse and human γδ IEL. This contrasts with diverse antigen recognition by clonally-restricted complementarity-determining regions (CDRs) 1-3 of TCRγδ. Hence, TCRγδ intrinsically combines innate and adaptive immunity by utilizing spatially distinct regions to discriminate non-clonal agonist-selecting elements from clone-specific ligands. The broader implications for antigen receptor biology are considered.

Human γδ T cells expressing a Vγ9Vδ2 T‐cell receptor (TCR) kill various tumour cells including autologous tumours. In addition to TCR‐dependent recognition, activation of NKG2D‐positive γδ T cells by tumour cell‐expressed NKG2D ligands can also trigger cytotoxic effector function. In this study, we investigated the involvement of TCR versus NKG2D in tumour cell recognition as a prerequisite to identify tumour types suitable for γδ T‐cell‐based immunotherapy. We have characterized epithelial tumour cells of different origin with respect to cell surface expression of the known NKG2D ligands MHC class I‐chain‐related antigens (MIC) A/B and UL16‐binding proteins (ULBP), and susceptibility to γδ T‐cell killing. Most tumour cells expressed comparable levels of MICA and MICB as well as ULBP with the exception of ULBP‐1 which was absent or only weakly expressed. Most epithelial tumours were susceptible to allogeneic γδ T‐cell lysis and in the case of an established ovarian carcinoma to autologous γδ T‐cell killing. Lysis of resistant cells was enhanced by pre‐treatment of tumour cells with aminobisphosphonates or pre‐activation of γδ T cells with phosphoantigens. A potential involvement of TCR and/or NKG2D was investigated by antibody blockade. These experiments revealed three patterns of inhibition, i.e. preferential inhibition by anti‐TCR antibody, preferential inhibition by anti‐NKG2D antibody, or additive blockade by anti‐TCR plus anti‐NKG2D antibodies. Our results indicate for the first time that the NKG2D pathway is involved in the lysis of different melanomas, pancreatic adenocarcinomas, squameous cell carcinomas of the head and neck, and lung carcinoma.

The interaction of the MHC class I-related chain molecules A and B (MICA and MICB) with the corresponding natural killer group 2, member D (NKG2D) receptor triggers cytotoxic effector activity of natural killer cells and certain T-cell subsets and provides a costimulatory signal for cytokine production. Thus, the presence of MICA=B on transformed cells contributes to tumor immunosurveillance. Consequently, the proteolytic cleavage of MICA=B is regarded as an important immune escape mechanism of various cancer cells. To investigate the molecular machinery responsible for the shedding of endogenous MICA=B, we analyzed different human tumor entities including mammary, pancreatic and prostate carcinomas. Flow cytometry and enzyme-linked immunosorbent assay (ELISA) revealed that all tested tumor cells constitutively expressed MICA and MICB on the cell surface and also released NKG2D ligands into the supernatant. We demonstrate that the "a disintegrin and metalloproteases" (ADAMs) 10 and 17 are largely responsible for the generation of soluble MICA=B. Pharmacological inhibition of metalloproteases reduced the level of released MICA=B and increased cell surface expression. Studies using RNA interference not only revealed a prominent role of ADAM10 and ADAM17 in NKG2D ligand shedding but also a tumor cell-specific role of ADAM10 and=or ADAM17 in shedding of MICA or MICB. Moreover, we report that in the prostate carcinoma cell line PC-3, MICA was not shed at all but rather was secreted in exosomes. These data indicate that the release of NKG2D ligands from individual tumor entities is by far more complex than suggested in previously reported MICA=B transfection systems.The activating natural killer group 2, member D (NKG2D) receptor is expressed on NK cells, NKT cells, gd T cells, CD8 1 T cells and a minor immunoregulatory subset of CD4 1 T cells. 1,2 The ligation of NKG2D costimulates T cells but also directly triggers cell-mediated cytotoxicity and cytokine release in NK cells. [3][4][5][6] Thus, despite some exceptions including gastrointestinal epithelium 7 and placenta, 8 the ligands for NKG2D are not expressed on healthy tissues to avoid inadvertent damage. However, NKG2D ligand (NKG2DL) expression can be induced in response to a variety of stimuli related to cellular stress such as heat shock, viral infection, DNA damage, oxidative stress and certain proinflammatory signals. 9,10 Of note, many tumors and precancerous lesions express NKG2D ligands presumably as a bystander effect of the oncogenic process itself. 11 As NKG2DL expression renders tumors susceptible to NKG2D 1 lymphocytes, the NKG2D system plays a pivotal role in immunosurveillance. 12 On the other hand, the sustained exposure to tumor cell-bound NKG2D ligands might also result in surface modulation and functional impairment of the NKG2D receptor and induce cross-tolerance of additional NK cell activation pathways. 13,14 A hallmark of the NKG2D system is the multitude of ligands identified so far. In humans, these include the MHC class I-related chain ...

TLR3 recognizes viral dsRNA and its synthetic mimetic polyinosinic-polycytidylic acid (poly(I:C)). TLR3 expression is commonly considered to be restricted to dendritic cells, NK cells, and fibroblasts. In this study we report that human γδ and αβ T lymphocytes also express TLR3, as shown by quantitative real-time PCR, flow cytometry, and confocal microscopy. Although T cells did not respond directly to poly(I:C), we observed a dramatic increase in IFN-γ secretion and an up-regulation of CD69 when freshly isolated γδ T cells were stimulated via TCR in the presence of poly(I:C) without APC. IFN-γ secretion was partially inhibited by anti-TLR3 Abs. In contrast, poly(I:C) did not costimulate IFN-γ secretion by αβ T cells. These results indicate that TLR3 signaling is differentially regulated in TCR-stimulated γδ and αβ T cells, suggesting an early activation of γδ T cells in antiviral immunity.

The ability of human gd T cells from healthy donors to kill pancreatic ductal adenocarcinoma (PDAC) in vitro and in vivo in immunocompromised mice requires the addition of gd T-cell-stimulating antigens. In this study, we demonstrate that gd T cells isolated from patients with PDAC tumor infiltrates lyse pancreatic tumor cells after selective stimulation with phosphorylated antigens. We determined the absolute numbers of gd T-cell subsets in patient whole blood and applied a real-time cell analyzer to measure their cytotoxic effector function over prolonged time periods. Because phosphorylated antigens did not optimally enhance gd T-cell cytotoxicity, we designed bispecific antibodies that bind CD3 or Vg9 on gd T cells and Her2/neu (ERBB2) expressed by pancreatic tumor cells. Both antibodies enhanced gd T-cell cytotoxicity with the Her2/Vg9 antibody also selectively enhancing release of granzyme B and perforin. Supporting these observations, adoptive transfer of gd T cells with the Her2/Vg9 antibody reduced growth of pancreatic tumors grafted into SCID-Beige immunocompromised mice. Taken together, our results show how bispecific antibodies that selectively recruit gd T cells to tumor antigens expressed by cancer cells illustrate the tractable use of endogenous gd T cells for immunotherapy.

Human Vγ9Vδ2 γδ T cells are selectively activated by bacterial phosphoantigens and aminobisphosphonates and exert potent cytotoxicity toward various tumor cells. In this study we have characterized the cytotoxic reactivity of γδ T cell lines established from healthy donors by stimulation with aminobisphosphonate alendronate toward melanoma MeWo and pancreatic adenocarcinomas Colo357 and PancTu1 lines in vitro and in vivo upon adoptive transfer into SCID mice. Lysis of all tumor cells was enhanced when γδ effector cells were preactivated with phosphoantigens. Recognition of MeWo was TCR dependent, as shown by anti-TCR Ab blockade, whereas only the phosphoantigen-mediated increased, but not the basal, lysis of Colo357 and PancTu1 was inhibited by anti-TCR Ab. Furthermore, lysis of Colo357, but not that of MeWo or PancTu1, was completely inhibited by the pan-caspase inhibitor zVAD, indicating different recognition and effector mechanisms involved in the γδ T cell/tumor cell interactions. Upon transfer into SCID mice, alendronate-activated γδ T cells given together with IL-2 and alendronate significantly prolonged the survival of SCID mice inoculated with human tumor cells. The best results were thus obtained when γδ T cells were repetitively given five times over a period of 30 days. With this protocol, human γδ T cells prolonged the mean survival of mice inoculated with MeWo melanoma from 28.5 to 87.3 days (p < 0.0001) and in the case of PancTu1 adenocarcinoma from 23.0 to 48.4 days (p < 0.0001). We conclude that an effective γδ T cell-based immunotherapy might require activation of endogenous γδ T cells with aminobisphosphonate (or phosphoantigen) and IL-2, followed by adoptive transfer of in vitro expanded γδ T cells.

γδ T lymphocytes play an important role in the immune defense against infection, based on the unique reactivity of human Vδ2Vγ9 γδ T cells toward bacterial phosphoantigens. Chemokines and their corresponding receptors orchestrate numerous cellular reactions, including leukocyte migration, activation, and degranulation. In this study we investigated the expression of various receptors for inflammatory and homeostatic chemokines on peripheral blood γδ T cells and compared their expression patterns with those on αβ T cells. Although several of the analyzed receptors (including CCR6, CCR7, CXCR4, and CXCR5) were not differentially expressed on γδ vs αβ T cells, γδ T cells expressed strongly increased levels of the RANTES/macrophage inflammatory protein-1α/-1β receptor CCR5 and also enhanced levels of CCR1–3 and CXCR1–3. CCR5 expression was restricted to Vδ2 γδ T cells, while the minor subset of Vδ1 γδ T cells preferentially expressed CXCR1. Stimulation with heat-killed extracts of Mycobacterium tuberculosis down-modulated cell surface expression of CCR5 on γδ T cells in a macrophage-dependent manner, while synthetic phosphoantigen isopentenyl pyrophosphate and CCR5 ligands directly triggered CCR5 down-modulation on γδ T cells. The functionality of chemokine receptors CCR5 and CXCR3 on γδ T cells was demonstrated by Ca2+ mobilization and chemotactic response to the respective chemokines. Our results identify high level expression of CCR5 as a characteristic and selective feature of circulating Vδ2 γδ T cells, which is in line with their suspected function as Th1 effector T cells.